Jan Brosda1, Thorsten Becker2, Mathis Richter3, Marie Jakobs3, Tina Hörbelt3, Ivo Bendix4, Laura Lückemann3, Manfred Schedlowski3,5, Martin Hadamitzky6. 1. Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universität Berlin, 14195, Berlin, Germany. 2. Institute of Biology, Department of Neurophysiology, Freie Universität Berlin, 14195, Berlin, Germany. 3. Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany. 4. Department of Pediatrics I/Experimental perinatal Neuroscience, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany. 5. Department of Clinical Neuroscience, Osher Center for Integrative Medicine, Karolinska Institutet, 17177, Stockholm, Sweden. 6. Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany. martin.hadamitzky@uk-essen.de.
Abstract
RATIONALE: Calcineurin is a protein regulating cytokine expression in T lymphocytes and calcineurin inhibitors such as cyclosporine A (CsA) are widely used for immunosuppressive therapy. It also plays a functional role in distinct neuronal processes in the central nervous system. Disturbed information processing as seen in neuropsychiatric disorders is reflected by deficient sensorimotor gating, assessed as prepulse inhibition (PPI) of the acoustic startle response (ASR). OBJECTIVE: Patients who require treatment with immunosuppressive drugs frequently display neuropsychiatric alterations during treatment with calcineurin inhibitors. Importantly, knockout of calcineurin in the forebrain of mice is associated with cognitive impairments and symptoms of schizophrenia-like psychosis as seen after treatment with stimulants. METHODS: The present study investigated in rats effects of systemic acute and subchronic administration of CsA on sensorimotor gating. Following a single injection with effective doses of CsA, adult healthy male Dark Agouti rats were tested for PPI. For subchronic treatment, rats were injected daily with the same doses of CsA for 1 week before PPI was assessed. Since calcineurin works as a modulator of the dopamine pathway, activity of the enzyme tyrosine hydroxylase was measured in the prefrontal cortex and striatum after accomplishment of the study. RESULTS: Acute and subchronic treatment with the calcineurin inhibitor CsA disrupted PPI at a dose of 20 mg/kg. Concomitantly, following acute CsA treatment, tyrosine hydroxylase activity was reduced in the prefrontal cortex, which suggests that dopamine synthesis was downregulated, potentially reflecting a stimulatory impact of CsA on this neurotransmitter system. CONCLUSIONS: The results support experimental and clinical evidence linking impaired calcineurin signaling in the central nervous system to the pathophysiology of neuropsychiatric symptoms. Moreover, these findings suggest that therapy with calcineurin inhibitors may be a risk factor for developing neurobehavioral alterations as observed after the abuse of psychomotor stimulant drugs.
RATIONALE: Calcineurin is a protein regulating cytokine expression in T lymphocytes and calcineurin inhibitors such as cyclosporine A (CsA) are widely used for immunosuppressive therapy. It also plays a functional role in distinct neuronal processes in the central nervous system. Disturbed information processing as seen in neuropsychiatric disorders is reflected by deficient sensorimotor gating, assessed as prepulse inhibition (PPI) of the acoustic startle response (ASR). OBJECTIVE:Patients who require treatment with immunosuppressive drugs frequently display neuropsychiatric alterations during treatment withcalcineurin inhibitors. Importantly, knockout of calcineurin in the forebrain of mice is associated withcognitive impairments and symptoms of schizophrenia-like psychosis as seen after treatment with stimulants. METHODS:The present study investigated in rats effects of systemic acute and subchronic administration of CsA on sensorimotor gating. Following a single injection with effective doses of CsA, adult healthy male Dark Agouti rats were tested for PPI. For subchronic treatment, rats were injected daily withthe same doses of CsA for 1 week before PPI was assessed. Since calcineurin works as a modulator of the dopamine pathway, activity of the enzyme tyrosine hydroxylase was measured in the prefrontal cortex and striatum after accomplishment of the study. RESULTS: Acute and subchronic treatment withthe calcineurin inhibitorCsA disrupted PPI at a dose of 20 mg/kg. Concomitantly, following acute CsA treatment, tyrosine hydroxylase activity was reduced in the prefrontal cortex, which suggests that dopamine synthesis was downregulated, potentially reflecting a stimulatory impact of CsA on this neurotransmitter system. CONCLUSIONS:The results support experimental and clinical evidence linking impaired calcineurin signaling in the central nervous system to the pathophysiology of neuropsychiatric symptoms. Moreover, these findings suggest that therapy withcalcineurin inhibitors may be a risk factor for developing neurobehavioral alterations as observed after the abuse of psychomotor stimulant drugs.
Entities:
Keywords:
Calcineurin; Cyclosporine A; Drug side effects; Prepulse inhibition; Sensorimotor gating
Authors: JoAnn Lindenfeld; Geraldine G Miller; Simon F Shakar; Ronald Zolty; Brian D Lowes; Eugene E Wolfel; Luisa Mestroni; Robert L Page; Jon Kobashigawa Journal: Circulation Date: 2004-12-14 Impact factor: 29.690
Authors: Martin Hadamitzky; Arne Herring; Julia Kirchhof; Ivo Bendix; Matthew J Haight; Kathy Keyvani; Laura Lückemann; Meike Unteroberdörster; Manfred Schedlowski Journal: Int J Neuropsychopharmacol Date: 2018-06-01 Impact factor: 5.176
Authors: Florian Uellendahl-Werth; Carlo Maj; Oleg Borisov; Simonas Juzenas; Eike Matthias Wacker; Isabella Friis Jørgensen; Tim Alexander Steiert; Saptarshi Bej; Peter Krawitz; Per Hoffmann; Christoph Schramm; Olaf Wolkenhauer; Karina Banasik; Søren Brunak; Stefan Schreiber; Tom Hemming Karlsen; Franziska Degenhardt; Markus Nöthen; Andre Franke; Trine Folseraas; David Ellinghaus Journal: Commun Biol Date: 2022-01-20